Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients

I. M. L. W. Keularts; S. Beguin; C. de Zwaan; H. C. Hemker

doi:10.1055/s-0037-1615213

Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients

I. M. L. W. Keularts, S. Beguin, C. de Zwaan, H. C. Hemker^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

82 Downloads (Pure)

Abstract

Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity: inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.

Original language	English
Pages (from-to)	370-371
Number of pages	2
Journal	Thrombosis and Haemostasis
Volume	80
Issue number	3
DOIs	https://doi.org/10.1055/s-0037-1615213
Publication status	Published - 1 Jan 1998

Access to Document

10.1055/s-0037-1615213

Full TextFinal published version, 29.8 KB

Cite this

@article{b0ab7b9ac53548c1a5af7332c80d2352,

title = "Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients",

abstract = "Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity: inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.",

author = "Keularts, {I. M. L. W.} and S. Beguin and {de Zwaan}, C. and Hemker, {H. C.}",

year = "1998",

month = jan,

day = "1",

doi = "10.1055/s-0037-1615213",

language = "English",

volume = "80",

pages = "370--371",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Georg Thieme Verlag",

number = "3",

}

TY - JOUR

T1 - Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients

AU - Keularts, I. M. L. W.

AU - Beguin, S.

AU - de Zwaan, C.

AU - Hemker, H. C.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity: inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.

AB - Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity: inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.

U2 - 10.1055/s-0037-1615213

DO - 10.1055/s-0037-1615213

M3 - Article

SN - 0340-6245

VL - 80

SP - 370

EP - 371

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

IS - 3

ER -